Rapport Pharma - Pangali EV/EBITDA RAPP

Patent protection for unique neurological drugs creates a significant barrier for competitors. Analyzing the EV/EBITDA chart on GURU.Markets, we see that the 0.00 mark captures this metric. Rapport Therapeutics, Inc. (RAPP) relies on its proprietary precision neurobiology ecosystem to develop exclusive treatments. High margins from global sales of approved molecules provide Rapport Therapeutics, Inc. (RAPP) with excellent business scalability.

This multiple compares the total enterprise value of the business with its operating profit before depreciation and amortization, allowing for an assessment of the real value of assets regardless of debt load and tax regime. By analyzing the EV/EBITDA ratio in light of the capital structure, an investor can determine the degree of overvaluation of Rapport Therapeutics (RAPP) in the context of future revenues from the sale of targeted neuropreparations for patients with neurological pathologies.